IMRX vs TXN · $124.2M cap vs P/E 52, rev $10.29B
Immuneering Corp (IMRX) versus Texas Instruments Incorporated (TXN) — a side-by-side from cached financials, not a winner call.
Immuneering Corp (IMRX) is a biotechnology company listed on US.
Texas Instruments Incorporated (TXN) is a semiconductors company listed on NASDAQ.
Latest reported IMRX revenue for 2023-12-31 was $0. Net income was -$53.5M. Revenue was down 100.0% from 2022-12-31 to 2023-12-31. IMRX currently screens at market cap $124.2M.
Latest reported TXN revenue for 2026-06-30 was $10.29B. Net income was $3.52B. TXN currently screens at market cap $274.74B and trailing P/E 51.7.
IMRX currently screens at market cap $124.2M. TXN currently screens at market cap $274.74B and trailing P/E 51.7.
Not investment advice. Open the IMRX and TXN stock pages for the full models.
Not investment advice.